US drugmaker AbbVie’s (NYSE: ABBV) hopes that Skyrizi (risankizumab) will help to replace revenues lost when Humira (adalimumab) competition starts to bite, have been boosted further.
The company has announced new two-year data on its use in plaque psoriasis at the World Congress of Dermatology (WCD).
Findings show that Skyrizi can not only offer skin clearance at two years of treatment for the majority of patients, but re-treatment complete following a relapse can help patients regain skin clearance in just 16 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze